Acceptability of treatment ‐ leaving the study early · schizophrenia
Maintenance treatment with antipsychotic drugs leads to lower leaving the study early: due to any reason (acceptability of… compared with placebo/no treatment (high certainty).
1 finding from 1 review
Satisfaction with treatment: leaving the study early Endpoint data (events) · people in the prodromal stage of psychosis
It is very uncertain whether group C other: integrated treatment changes satisfaction with treatment: leaving the study early Endpoint data… compared with standard treatment (very low certainty).
1 finding from 1 review
Satisfaction with treatment: leaving the study early FACT Long‐term · people in the prodromal stage of psychosis
It is very uncertain whether group C other: family treatment changes satisfaction with treatment: leaving the study early FACT Long‐term compared with enhanced care (very low certainty).
1 finding from 1 review
Unacceptability of treatment (drop-outs / leaving study early) · patients with schizophrenia
It is very uncertain whether BENZODIAZEPINES AS SOLE TREATMENT changes leaving the study early due to any reason (overall acceptability of… compared with PLACEBO (very low certainty).
1 finding from 1 review
Adverse effects (drop‐outs due to adverse effects4) · patients with schizophrenia
1 finding from 1 review
Lost to treatment · people with both severe mental illness and substance misuse
It is very uncertain whether non‐integrated models of care ‐ Assertive community treatment… changes leaving the study early: Lost to treatment compared with standard care (very low certainty).
1 finding from 1 review
Satisfaction with treatment: leaving the study early Endpoint data (events) · people with treatment‐resistant schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Satisfaction with treatment: leaving the study early Endpoint data (events) · people with treatment‐resistant schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Satisfaction with treatment: leaving the study early Endpoint data (events) · people with treatment‐resistant schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Leaving the study early · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Satisfaction and acceptability of treatment (medium term) ‐ leaving the study early · people with treatment‐resistant schizophrenia
It is very uncertain whether ECT plus standard care changes satisfaction and acceptability of treatment (medium term) ‐ leaving… compared with standard care (very low certainty).
1 finding from 1 review
Leaving the study early · people with treatment‐resistant schizophrenia
It is very uncertain whether CLOZAPINE + AMISULPIRIDE changes leaving the study early: acceptability of treatment ‐ as measured by… compared with CLOZAPINE + QUETIAPINE (Genc 2007) (very low certainty).
1 finding from 1 review
Leaving the study early · people with treatment‐resistant schizophrenia
1 finding from 1 review
Leaving the study early · people with treatment‐resistant schizophrenia
It is very uncertain whether CLOZAPINE + ZIPRASIDONE changes leaving the study early: acceptability of treatment ‐ as measured by… compared with CLOZAPINE + QUETIAPINE (Wen 2015) (very low certainty).
1 finding from 1 review
Acceptability of treatment ‐ leaving the study early · people with treatment‐resistant schizophrenia
It is very uncertain whether CLOZAPINE + RISPERIDONE changes leaving the study early: acceptability of treatment ‐ as measured by… compared with CLOZAPINE + ZIPRASIDONE (Kuwilsky 2010) (very low certainty).
1 finding from 1 review
Acceptability of treatment ‐ leaving the study early · people with treatment‐resistant schizophrenia
It is very uncertain whether CLOZAPINE + ARIPIPRAZOLE changes leaving the study early: acceptability of treatment ‐ as measured by… compared with CLOZAPINE + HALOPERIDOL (Cipriani 2013) (very low certainty).
1 finding from 1 review
Leaving the study early · patients with sexual dysfunction due to antipsychotic drug therapy
It is very uncertain whether ADJUNCTIVE TREATMENT ‐ SPECIFIC: SILDENAFIL changes leaving the study early compared with PLACEBO (very low certainty).
1 finding from 1 review
Leaving the study early/ loss to · people with psychosis
1 finding from 1 review
Leaving the study early · patients with sexual dysfunction due to antipsychotic drug therapy
1 finding from 1 review
Leaving the study early · chronic schizophrenia patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether anticholinergic medication changes acceptability of the treatment: leaving the study early compared with other treatments (very low certainty).
1 finding from 1 review